NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation ...

Perspective Therapeutics announced data presentations at ASCO 2025 for its cancer treatment programs [212Pb]VMT-α-NET and [212Pb]VMT01. Perspective Therapeutics, Inc. announced that it will present ...

Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based ...

The success of an undergraduate research conference is due in large part to the many judges who provide feedback to the student presenters throughout the conference. In addition to student feedback, ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data ...

TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology 2025 annual meeting in San Diego, California, from ...

Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...

Servier today announced that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2025, in Orlando, Florida. Presentations will ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new six-year data from the ULTIMATE I & II Phase 3 trials ...

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased ...

- 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition - - Axatilimab abstracts highlight ...